PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice - Wikidata - wikimedia - TriplyDB

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

http://www.wikidata.org/entity/Q28362804

about

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice PPARs and the cardiovascular system Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice Opportunities for the treatment of inflammation in cardiovascular disease Metabolic syndrome, inflammation and atherosclerosis PPARalpha governs glycerol metabolism Impaired expression of NADH dehydrogenase subunit 1 and PPARgamma coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice PPARalpha deficiency in inflammatory cells suppresses tumor growth.Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases.PPARα-independent actions of omega-3 PUFAs contribute to their beneficial effects on adiposity and glucose homeostasis Mice deficient in group VIB phospholipase A2 (iPLA2gamma) exhibit relative resistance to obesity and metabolic abnormalities induced by a Western diet.Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase.Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha)-deficient mice.Insulin resistance and atherosclerosis.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice.Inhibition of gluconeogenic genes by calcium-regulated heat-stable protein 1 via repression of peroxisome proliferator-activated receptor α.Aryl hydrocarbon receptor deficiency enhances insulin sensitivity and reduces PPAR-α pathway activity in mice.Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis.Lipid-induced mitochondrial stress and insulin action in muscle Mitochondrial dysfunction and mitochondrial DNA mutations in atherosclerotic complications in diabetes PPARalpha in atherosclerosis and inflammation.Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications.Metabolic crosstalk between choline/1-carbon metabolism and energy homeostasis.Measuring biomarkers to assess the therapeutic effects of PPAR agonists?PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice PPARs and the kidney in metabolic syndrome.Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.

P2860

Q24541529-CE3606B9-0CB8-439D-90DE-FFAC46A80A88 Q24551979-6D022445-F0D6-4D8A-A275-B83EDC52B64C Q24642728-9111ABE0-292D-4790-9EF9-B86D9ECCAE1E Q24655769-6E3F5BDF-A322-40A0-8515-A93AB9FF6459 Q24798075-150B0501-0FDB-4826-BC1F-BBDE43A54183 Q27318595-1EB98640-88A3-475B-B950-8D60F957BFA3 Q28192292-BA88AB33-D77F-403B-A38D-FB485899FE42 Q28219348-521C54B5-463A-4FBA-AB01-6A6917871F3F Q28507952-328DD2FC-BEB6-4521-A7CE-29315F96FE87 Q28578564-837A4F76-EDC8-46DF-AF01-E8C1550DC382 Q30353176-CB3C6EF1-4A54-482A-A835-D4565C75E35E Q30513404-28D15829-E23F-4887-BC6F-A93F91D5C789 Q33275971-29B5312C-9613-418E-A688-9FFAFB8DC3DD Q33320681-85BB4342-19F5-4F7B-A69D-0159FDA12B88 Q33569870-4DB8648B-B4BD-4961-82CA-7A65B88EBCE6 Q33832975-4BCEC701-6A99-4AD3-B892-16FA2D43C25A Q33916535-4BC55218-F39D-4881-9672-43A527FE4A69 Q34004031-F5FE1F14-9C53-4728-BF14-2153652E7045 Q34450240-9F6E00C0-EB44-49F6-8F80-399544D88F4B Q34492025-F88A9EF8-6B0E-42EA-B573-085EF7248242 Q34511046-6AB52207-6AF3-408F-8BB7-7D43B675AB4D Q34617976-DE5F8185-FD3A-4020-B494-677DDA97EB5E Q34698887-8B66CAC9-5AD7-4AB4-8A1A-0160EFA9BCB5 Q34808268-533EF842-D8AD-4A78-8C6E-F534E9373ACA Q35000567-B15A9E5B-2158-4C47-8F35-991709B6841C Q35144122-0EAEC19F-C65F-4212-B75F-2B00DC6266D5 Q35562621-AE2799BA-0CD9-40CA-B967-2A325123A9EA Q35682887-D52E73BE-99EB-4004-9495-6BF506508341 Q35921527-EC432351-0901-442A-A83B-B8ECD88C4A78 Q35947486-2624AEE0-F620-4AD9-9FAC-B4F91C95F18D Q35999426-AFF44DC5-A1D3-4A03-88AE-0F838F1B85E2 Q36154953-641CACA7-2326-4174-AEC1-372F8C5DE504 Q36447954-E0EBD913-0CCA-41EF-A03D-51CFB767AAA4 Q36458927-D10BD72A-8797-4E98-AC59-773B3A9FCE6D Q36521113-70D824B2-61DE-4C2F-BFFA-A8E88CE14416 Q36759438-E698ACDD-35DB-4829-AF4A-47D66616540C Q37012012-75F6CF82-B6D6-4B16-A765-15E64A59DB50 Q37036060-72DFD41E-EE34-4DFF-BE75-7F722AA6F8E9 Q37072216-97669DA5-AC2A-42C9-BCEA-E7ADA4A4404C Q37242352-15C4775D-1320-4FE4-8721-B07B30FED580

P2860

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

http://www.wikidata.org/entity/Q28362804

description

2001 nî lūn-bûn

@nan

2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@ast

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@en

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@nl

type

label

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@ast

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@en

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@nl

prefLabel

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@ast

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@en

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@nl

P1433

Q28362804-98F71B12-F828-44F9-A5E5-FBC06ACE714E

P1476

Q28362804-08C79ED5-37D1-46F1-8CE3-C06B4D483818

P2093

Q28362804-302A25B7-3E4B-46D7-87D6-8B5AD40A9E41

Q28362804-35DE5C93-C4CC-43A5-A329-41328B0C1C4E

Q28362804-4C21A6A0-CCBB-482A-8C81-EBFD16BF039F

Q28362804-6455D000-C559-4381-A415-CD4E547F6EE7

Q28362804-6AB49CA9-E852-486E-80A7-97FECCF63BC3

Q28362804-8DEF0477-A146-4567-AB96-38F48D1DAF1B

Q28362804-C5C310F5-B6E2-4E06-A56F-FBA6B5573315

Q28362804-F2E6C9D4-17B8-4137-A24F-FF0A0FF40321

Q28362804-F9B44B21-E2A7-4C91-B397-6DCB0702BA33

Q28362804-FA2A5F2D-6802-4393-879D-136FD0974F75

P2860

Q28362804-01605A27-DE92-4553-A62C-2AD4F85483F0

Q28362804-0255E256-3706-45EB-B197-61946EC78D43

Q28362804-02C77132-0060-4161-BF07-DD93DEAAD19A

Q28362804-02E18037-EB90-4D47-A174-EE18D11142CE

Q28362804-03A4C3BE-7A51-4B70-8C47-EF098CB4DA95

Q28362804-10626DCC-6D3E-4D7B-A33B-09D0958A4C21

Q28362804-150B075C-67A8-4AF3-AC89-691748FBA496

Q28362804-1C21265A-7C4C-47ED-AB47-C2D139228B8D

Q28362804-1F6A7048-3232-4FDC-A8BE-7D07CE74E010

Q28362804-27AFB437-8762-4EAB-803F-D70BD2DFC10B

P304

Q28362804-60B67895-9F0D-45C3-8438-938B8F28606E

P31

Q28362804-C0E8A5DF-D128-42A9-9324-AB43A5EC35C7

P356

Q28362804-C024C951-8513-45AC-BDC3-37A6845C4B2C

P407

Q28362804-E0DA69D3-C313-465A-95BD-3CFBC729088C

P433

Q28362804-1F54A106-5D7A-4038-BE12-0EA477A54DF2

P478

Q28362804-A6EFA111-8218-46D1-9B44-ECF0757360CC

P577

Q28362804-F83AAE0C-900B-4A97-9EDA-8A11F086A942

P5875

Q28362804-F7330F3D-7264-4BD1-8651-2073229934B7

P698

Q28362804-6A9495A5-63B0-48DC-96DC-03B5B3595460

P921

Q28362804-0BE26E50-DACA-493A-8D13-B49B9E74A61D

Q28362804-8841A827-DC21-4405-8207-AE76C2965719

P932

Q28362804-DBBF51DC-6792-4EE0-8666-B8B0352291D1

P356

P1433

Journal of Clinical Investigation

P1476

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

@en

P2093

C Bernal-Mizrachi

http://www.w3.org/2001/XMLSchema#string

C F Semenkovich

http://www.w3.org/2001/XMLSchema#string

C Feng

http://www.w3.org/2001/XMLSchema#string

D P Kelly

http://www.w3.org/2001/XMLSchema#string

F Zhang

http://www.w3.org/2001/XMLSchema#string

K Tordjman

http://www.w3.org/2001/XMLSchema#string

L Zemany

http://www.w3.org/2001/XMLSchema#string

S Weng

http://www.w3.org/2001/XMLSchema#string

T C Leone

http://www.w3.org/2001/XMLSchema#string

T Coleman

http://www.w3.org/2001/XMLSchema#string

P2860

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

P304

1025-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI11497

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12027159

http://www.w3.org/2001/XMLSchema#string

P698

11306606

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

199556

http://www.w3.org/2001/XMLSchema#string